PLAQUE PSORIASIS
Clinical trials for PLAQUE PSORIASIS explained in plain language.
Never miss a new study
Get alerted when new PLAQUE PSORIASIS trials appear
Sign up with your email to follow new studies for PLAQUE PSORIASIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill aims to clear skin and improve life for psoriasis patients
Disease control Not yet recruitingThis study is testing an investigational oral medication called D-2570 for people with moderate to severe plaque psoriasis. It will compare the new drug's effectiveness and safety against a placebo (a dummy pill) and an existing approved medication. The goal is to see if D-2570 c…
Matched conditions: PLAQUE PSORIASIS
Phase: PHASE3 • Sponsor: InventisBio Co., Ltd • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC
-
Double trouble treatment: new combo targets skin and cholesterol together
Disease control Not yet recruitingThis study is testing whether adding a cholesterol-lowering drug (recaticimab) to a standard psoriasis medication (vunakizumab) works better for people who have both conditions. It will involve 40 adults with moderate-to-severe plaque psoriasis and high cholesterol. The main goal…
Matched conditions: PLAQUE PSORIASIS
Phase: PHASE4 • Sponsor: Xiangya Hospital of Central South University • Aim: Disease control
Last updated Mar 30, 2026 14:31 UTC
-
New psoriasis drug enters Mid-Stage testing
Disease control Not yet recruitingThis study aims to test if an investigational drug called HSK47388 is effective and safe for treating moderate to severe plaque psoriasis. It will involve about 220 adults with significant skin coverage and compare the drug against a placebo over 16 weeks. The main goal is to see…
Matched conditions: PLAQUE PSORIASIS
Phase: PHASE2 • Sponsor: Haisco Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Mar 24, 2026 12:01 UTC
-
New drug seeks to clear severe skin plaques
Disease control Not yet recruitingThis study aims to find the best dose of an investigational drug called ORKA-002 for treating moderate-to-severe plaque psoriasis. About 160 adults with this skin condition will receive either one of three different doses of the drug or a placebo for 16 weeks. Researchers will me…
Matched conditions: PLAQUE PSORIASIS
Phase: PHASE2 • Sponsor: Oruka Therapeutics, Inc. • Aim: Disease control
Last updated Mar 20, 2026 14:47 UTC